NYSE$CLW
Clearwater Paper Corporation · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Clearwater Paper reported financial results for the fourth quarter and year ended December 31, 2024, with a significant increase in net income driven by the gain on sale of its tissue division.
Clearwater Paper reported a transformational year in 2024, marked by the acquisition of the Augusta, Georgia paperboard facility and the divestiture of its tissue business. The company's fourth-quarter net income significantly increased to $199.1 million, primarily due to a $307.2 million gain on the sale of its tissue division, despite lower sales prices and higher maintenance costs.
- Net income from total operations for Q4 2024 was $199.1 million, a substantial increase from $18 million in Q4 2023, driven by the gain on sale of the tissue division.
- Sales volumes for paperboard increased by 63% in Q4 2024 to 306,692 tons compared to the same period last year.
- Paperboard average net selling price decreased by 9% to $1,177 per ton in Q4 2024 compared to Q4 2023.
- Adjusted EBITDA from total operations decreased to $21 million in Q4 2024 from $63 million in Q4 2023, primarily due to planned major maintenance at the Augusta facility and lower sales prices.
Headline financials
Revenue & EPS history
Clearwater Paper · Revenue · Quarterly
$483
Forward guidance
Clearwater Paper anticipates continued challenging SBS industry conditions with supply exceeding demand but remains optimistic about future growth in paperboard packaging. The company is implementing actions to reduce fixed costs and invest in assets to maintain competitiveness.
Tailwinds
- Focusing strategy on becoming a paperboard packaging company.
- Increased paperboard capacity by nearly 75% with the Augusta acquisition.
- Improved geographic footprint in North America.
- Anticipated cost savings of $30 to $40 million in 2025 from fixed cost reductions.
- Continued investment in assets to ensure long-term competitiveness.
Headwinds
- Challenging SBS industry conditions with supply exceeding demand.
- Near-term margin pressure due to market conditions.
- Lower sales prices impacting profitability.
- Higher maintenance costs impacting profitability.
- Divestiture of tissue operations may reduce product diversification.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
-2.7%
Avg return
Earnings day
-4.4%
Avg return
5 days after
-4.0%
Avg return
30 days after
39%
26 / 66 earnings
Positive
+24.1%
Q1 2022
Best reaction
-33.5%
Q1 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -13.5% | -14.3% | +9.8% | |
| Q4 2025 | -8.6% | -15.1% | -26.6% | |
| Q3 2025 | -8.5% | -6.2% | -5.8% | |
| Q2 2025 | -18.4% | -24.9% | -26.7% | |
| Q1 2025 | +7.4% | +4.0% | +15.1% | |
| Q4 2024 | -8.4% | -3.9% | -17.6% | |
| Q3 2024 | +8.3% | +4.8% | +5.0% | |
| Q2 2024 | -23.3% | -34.5% | -39.1% | |
| Q1 2024 | +12.0% | +12.4% | +30.3% | |
| Q4 2023 | +3.4% | +7.5% | +21.7% | |
| Q3 2023 | -2.1% | +3.1% | +1.2% | |
| Q2 2023 | +14.8% | +10.9% | +18.8% | |
| Q1 2023 | -15.9% | -12.2% | -18.7% | |
| Q4 2022 | -0.2% | -1.0% | -10.8% | |
| Q3 2022 | -15.1% | -10.4% | -10.4% | |
| Q2 2022 | +15.3% | +20.1% | +18.4% | |
| Q1 2022 | +24.1% | +20.8% | +28.6% | |
| Q4 2021 | -12.7% | -7.4% | -6.0% | |
| Q3 2021 | +0.4% | -6.5% | +0.5% | |
| Q2 2021 | +2.1% | +8.4% | +18.5% | |
| Q1 2021 | -10.0% | -14.0% | -16.4% | |
| Q4 2020 | -18.7% | -15.1% | -11.4% | |
| Q3 2020 | -12.2% | -13.2% | -8.0% | |
| Q2 2020 | +2.5% | -4.7% | -14.1% | |
| Q1 2020 | +21.2% | +21.5% | +36.5% | |
| Q4 2019 | +10.2% | +11.2% | -18.5% | |
| Q3 2019 | +2.2% | -0.4% | +6.1% | |
| Q2 2019 | -13.9% | -0.3% | -18.5% | |
| Q1 2019 | -10.7% | -3.7% | -20.1% | |
| Q4 2018 | -16.0% | -17.0% | -25.4% | |
| Q3 2018 | -6.6% | -6.3% | -0.9% | |
| Q2 2018 | +11.9% | +14.8% | +28.5% | |
| Q1 2018 | -33.5% | -40.3% | -35.8% | |
| Q4 2017 | -25.1% | -23.0% | -13.8% | |
| Q3 2017 | +3.2% | +4.5% | +4.0% | |
| Q2 2017 | -9.2% | -9.0% | -6.6% | |
| Q1 2017 | -13.4% | -12.6% | -18.8% | |
| Q4 2016 | -6.7% | -3.9% | -17.3% | |
| Q3 2016 | -14.7% | -15.3% | -3.7% | |
| Q2 2016 | -7.1% | -5.4% | -11.0% | |
| Q1 2016 | +10.1% | — | — | |
| Q4 2015 | -5.9% | — | — | |
| Q3 2015 | +1.2% | — | — | |
| Q2 2015 | +10.2% | — | — | |
| Q1 2015 | +1.8% | — | — | |
| Q4 2014 | -17.4% | — | — | |
| Q3 2014 | +0.4% | — | — | |
| Q2 2014 | +12.0% | — | — | |
| Q1 2014 | -1.4% | — | — | |
| Q4 2013 | +9.6% | — | — | |
| Q3 2013 | +8.3% | — | — | |
| Q2 2013 | -0.7% | — | — | |
| Q1 2013 | -8.6% | — | — | |
| Q4 2012 | +4.3% | — | — | |
| Q3 2012 | -6.6% | — | — | |
| Q2 2012 | +4.9% | — | — | |
| Q1 2011 | -0.9% | — | — | |
| Q1 2012 | +7.2% | — | — | |
| Q4 2009 | -0.4% | — | — | |
| Q1 2010 | -0.4% | — | — | |
| Q4 2011 | -0.4% | — | — | |
| Q3 2011 | -1.8% | — | — | |
| Q3 2010 | -1.8% | — | — | |
| Q2 2010 | -5.2% | — | — | |
| Q4 2010 | -5.2% | — | — | |
| Q2 2011 | -5.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro